Poor Oral Health Tied to Worse Alzheimer's Cognition But Interventions Fall Short
A scoping review of 11 studies finds consistent links between oral disease and AD severity, but no clear proof that treating oral health improves cognition.
Summary
This scoping review analyzed 11 studies published between 2015 and 2025 examining the relationship between oral health and Alzheimer's disease (AD) cognition. Researchers found that poor oral health — including tooth loss, periodontal disease, and impaired chewing — was consistently associated with worse cognitive and functional outcomes. However, only two studies evaluated actual oral health interventions, and neither produced clear evidence of cognitive improvement. Most evidence remained observational and cross-sectional, limiting causal conclusions. Proposed mechanisms — including systemic inflammation, microbial translocation via Porphyromonas gingivalis, and oral microbiome dysbiosis — were rarely measured directly. The authors conclude that while a plausible mouth–brain axis exists, rigorous randomized trials with standardized cognitive and mechanistic outcomes are urgently needed before oral health can be called a therapeutic target in AD.
Detailed Summary
Alzheimer's disease (AD) affects tens of millions worldwide, and with global prevalence projected to exceed 150 million by 2050, identifying modifiable risk factors is critical. Oral health has attracted growing attention as one such factor: periodontal disease, tooth loss, impaired mastication, and oral microbiome dysbiosis have all been epidemiologically linked to cognitive impairment and dementia. The proposed biological bridge — the 'mouth–brain axis' — encompasses systemic inflammation, microbial translocation, and vascular and immune dysregulation. Notably, Porphyromonas gingivalis, a key periodontal pathogen, has been detected in the brains of individuals with AD, and its virulence factors have been implicated in amyloid-β and tau pathology, lending mechanistic plausibility to the association.
This scoping review, conducted by researchers at Roseman University and the University of Utah, followed the Arksey and O'Malley framework and reported under PRISMA-ScR guidelines. Searches in PubMed, Scopus, and Web of Science (January 2015–August 2025) initially returned 849 records. After title/abstract and full-text screening, 11 studies met inclusion criteria: one randomized controlled trial (RCT), one nonrandomized clinical trial, and nine observational studies (cross-sectional, case–control, and retrospective cohort designs). Sample sizes ranged from small clinical cohorts of fewer than 32 participants to one massive retrospective cohort — Kulkarni et al.'s TriNetX analysis — involving a poor oral health cohort of 1,232,751 adults aged ≥60 years matched to comparator groups to evaluate subsequent AD risk.
Across all 11 studies, poor oral health was consistently associated with worse cognitive, functional, or neuropsychiatric status. Common findings included increased periodontal disease burden, greater tooth loss, impaired masticatory performance, reduced salivary flow, altered oral microbiota composition, and heightened dependence on caregiver-assisted oral hygiene. Several studies reported statistically significant associations between oral health measures and cognitive or behavioral outcomes as measured by global screening instruments — most commonly the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) — and staging tools including the Clinical Dementia Rating (CDR) and Functional Assessment Staging Tool (FAST). Domain-specific neuropsychological assessments were rarely employed.
Only two studies evaluated structured oral health interventions. One nonrandomized study assessed prosthodontic rehabilitation using removable partial or complete dentures in individuals with mild AD. The second, the sole RCT, evaluated a multicomponent oral health program combining structured oral care support, self-care routines, and oral health education in a long-term care setting. Both interventions improved oral hygiene metrics and functional measures but yielded limited and inconsistent evidence of cognitive benefit. No included study evaluated intensive periodontal therapy paired with longitudinal cognitive follow-up in a rigorously randomized design. Proposed mechanistic pathways — including inflammatory biomarkers, oral microbiome data, and neuroimaging — were infrequently measured, leaving the biological underpinnings largely inferred rather than directly tested.
Implementation challenges were an important secondary theme. Caregiver burden, patient resistance to oral care, and logistical barriers in institutional settings recurred across studies. Several studies noted that functional and nutritional correlates of oral health — such as masticatory performance, dietary modification toward soft foods, and serum albumin levels — may serve as mediators between oral disease and cognitive or systemic outcomes, suggesting multifactorial pathways that future trials should account for. The authors conclude that while the observational evidence is consistent and the mechanistic rationale is compelling, the causal direction remains unresolved: oral decline may reflect disease progression rather than drive it. Large, adequately powered RCTs integrating standardized cognitive assessments with mechanistic biomarker outcomes are essential to determine whether oral health represents a genuinely modifiable therapeutic target in AD.
Key Findings
- Across all 11 included studies, poor oral health — including tooth loss, periodontal disease, and impaired mastication — was consistently associated with worse cognitive or functional outcomes in Alzheimer's disease patients.
- Only 2 of 11 studies evaluated structured oral health interventions; neither produced clear or consistent evidence of cognitive improvement despite improvements in oral hygiene metrics.
- The sole RCT in the review evaluated a multicomponent oral care program in a long-term care setting; cognitive benefit was limited and inconclusive.
- Kulkarni et al.'s retrospective TriNetX cohort — the largest included study — analyzed over 1.2 million adults aged ≥60 with poor oral health matched to comparators to assess subsequent AD risk, representing the broadest epidemiological signal in the review.
- Porphyromonas gingivalis, detected in AD brains, was specifically implicated in amyloid-β and tau pathology, yet direct mechanistic measurements (inflammatory biomarkers, microbiome data) were infrequently reported across included studies.
- Global cognitive screening tools (MMSE, MoCA) were the predominant outcome measures; domain-specific neuropsychological assessments were rarely used, limiting interpretation of cognitive impact.
- Caregiver burden and patient resistance to oral care were identified as consistent implementation barriers in institutional and dependent-care settings across multiple studies.
Methodology
This scoping review followed the Arksey and O'Malley framework and PRISMA-ScR reporting guidelines, with pre-registration on the Open Science Framework. Searches spanned PubMed, Scopus, and Web of Science from January 2015 to August 2025, yielding 849 initial records; 11 studies met inclusion criteria after independent screening by three reviewers. The included studies comprised one RCT, one nonrandomized trial, and nine observational studies with highly heterogeneous designs and sample sizes. Formal risk-of-bias assessment and meta-analysis were not performed, consistent with scoping review methodology.
Study Limitations
The review is limited by the small number of eligible studies (n=11), heavy reliance on observational and cross-sectional designs that preclude causal inference, and the predominant use of global cognitive screening tools rather than sensitive neuropsychological batteries. Only two interventional studies were identified, neither of which was adequately powered or methodologically rigorous enough to draw firm conclusions about cognitive benefit. The authors reported no external funding or conflicts of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: